Biology:Fluzone

From HandWiki
A 5cc vial of Fluzone

Fluzone is a brand of influenza vaccine, distributed by Sanofi Pasteur. It is a split-virus vaccine that is produced by chemical disruption of the influenza virus. Therefore, it is incapable of causing influenza.

Description

Fluzone is typically administered in a single dose by intramuscular injection;[1] an intradermal injection is also available.[2] It is presented as a 0.25 ml syringe for pediatric use, as a 0.5 ml syringe for adults and children, as a 0.5 ml vial for adults and children, and as a 5 ml vial for adults and children.[1] Fluzone must be refrigerated under temperatures from 2 to 8 °C (36 to 46 °F) and is inactivated by freezing. Fluzone was initially approved in 1980 by the FDA.[1]

Adverse effects

The following adverse effects have been reported:[1]

High-dose vaccine

A high-dose vaccine (Fluzone High-Dose) four times the strength of standard flu vaccine was approved by the FDA in 2009.[3][4] This vaccine is intended for people 65 and over, who typically have weakened immune response due to normal aging. The vaccine produces a greater immune response than standard vaccine. According to the CDC,[5] "a study published in the New England Journal of Medicine[6] [in August, 2014] indicated that the high-dose vaccine was 24.2% more effective in preventing flu in adults 65 years of age and older relative to a standard-dose vaccine." CDC recommends the high-dose vaccine for people 65 and over but expresses no preference between it and standard vaccine. Further studies were underway (As of 2014).

References

  1. 1.0 1.1 1.2 1.3 "Fluzone Prescribing Information" . Sanofi Pasteur. June 2012.
  2. "Fluzone intradermal vaccine website". Sanofi Pasteur.
  3. "FDA Approves A High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older" (Press release). U.S. Food and Drug Administration (FDA). December 23, 2009.
  4. Centers for Disease Control and Prevention (CDC) (April 2010). "Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010". MMWR. Morbidity and Mortality Weekly Report 59 (16): 485–6. PMID 20431524. https://www.cdc.gov/mmwr/PDF/wk/mm5916.pdf. 
  5. "Fluzone High–Dose Seasonal Influenza Vaccine" Centers for Disease Control and Prevention (CDC)
  6. "Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults"

External links